Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16496 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Min Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Anticonvulsants, Antiviral Agents, Seizures, Indoles. Die Arbeit nennt 51 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study.
Abstract (Originalsprache)
Background and purpose Sodium channel blockers (SCBs) have traditionally been utilized as anti‐seizure medications by primarily targeting the inactivation process. In a drug discovery project aiming at finding potential anticonvulsants, we have identified arbidol, originally an antiviral drug, as a potent SCB. In order to evaluate its anticonvulsant potential, we have thoroughly examined its biophysical properties as well as its effects on animal seizure models. Experimental approach Patch clamp recording was used to investigate the electrophysiological properties of arbidol, as well as the binding and unbinding kinetics of arbidol, carbamazepine and lacosamide. Furthermore, we evaluated the anticonvulsant effects of arbidol using three different seizure models in male mice. Key results Arbidol effectively suppressed neuronal epileptiform activity by blocking sodium channels. Arbidol demonstrated a distinct mode of action by interacting with both the fast and slow inactivation of Na v 1.2 channels compared with carbamazepine and lacosamide. A kinetic study suggested that the binding and unbinding rates might be associated with the specific characteristics of these three drugs. Arbidol targeted the classical binding site of local anaesthetics, effectively inhibited the gain‐of‐function effects of Na v 1.2 epileptic mutations and exhibited varying degrees of anticonvulsant effects in the maximal electroshock model and subcutaneous pentylenetetrazol model but had no effect in the pilocarpine‐induced status epilepticus model. Conclusions and implications Arbidol shows promising potential as an anticonvulsant agent, providing a unique mode of action that sets it apart from existing SCBs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
ORCID-Profile: Haibo Yu
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study
Zitieren
APA
Li, M., Jin, Y., Wu, J., Zhao, M., Yu, K., & Yu, H. (2024). Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity. British Journal of Pharmacology. https://doi.org/10.1111/bph.16496
Vancouver
Li M, Jin Y, Wu J, Zhao M, Yu K, Yu H. Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity. British Journal of Pharmacology. 2024. doi:10.1111/bph.16496
BibTeX
@article{Li2024,
author = {Li, Min and Jin, Yuchen and Wu, Jun and Zhao, Miao and Yu, Kexin and Yu, Haibo},
title = {Arbidol, an antiviral drug, identified as a sodium channel blocker with anticonvulsant activity},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16496}
}
EUVIMED